Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients

American Journal of Transplantation

Volumn 14, Issue 5, 2014, Pages 1129-1135

  Terrault, N ^a   Reddy, K R ^b   Poordad, F ^c   Curry, M ^d   Schiano, T ^e   Johl, J ^f   Shaikh, O ^g   Dove, L ^h   Shetty, K ⁱ   Millis, M ^j   Schiff, E ^k   Regenstein, F ^l   Barnes, D ^m   Barin, B ⁿ   Peters, M ^a   Roland, M ^a   Stock, P ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e Division of Liver Diseases   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

ⁱ GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^l TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m LERNER RESEARCH INSTITUTE   (United States)

ⁿ EMMES CORPORATION   (United States)

more..

Author keywords

antiviral therapy; histologic response; Sustained virologic response

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; CHILD; COMPLICATION; DRUG COMBINATION; FEMALE; FOLLOW UP; GENETICS; GRAFT RECIPIENT; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; DNA, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SURVIVAL RATE; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899458455     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12668     Document Type: Article

References (14)

1. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transplant 2012; 18: 716-726.
2. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study. Am J Transplant 2012; 12: 1866-1876.
3. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47: 407-417.
4. Berenguer M., Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287.
5. Xirouchakis E, Triantos C, Manousou P, et al. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: Systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709.
6. Ragni M, Belle S, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420.
7. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol 2014; 60: 78-86.
8. Pungpapong S, Aqel BA, Koning L, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700.
9. Ludwig J., The nomenclature of chronic viral hepatitis: An obituary. Gastroenterology 1993; 105: 274-278.
10. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292: 2839-2848.
11. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-459.
12. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946-1952.
13. Mathias A, Cornpropst M, Clemons D, et al. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants, cyclosporine A or tacrolimus in healthy volunteers. Hepatology 2012; 56(Abstract #1869): 1063.
14. Kirby B, Mathias A, Rossi S, Moyer C, Shen G, Kearney B., No clinically significant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla®, rilpivirine, darunavir/ritonavir or raltegravir in healthy volunteers. Hepatology 2012; 56(Suppl): A1678.